Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Current Assets (2016 - 2025)

Catalyst Pharmaceuticals' Current Assets history spans 16 years, with the latest figure at $894.0 million for Q4 2025.

  • For Q4 2025, Current Assets rose 43.36% year-over-year to $894.0 million; the TTM value through Dec 2025 reached $894.0 million, up 43.36%, while the annual FY2025 figure was $894.0 million, 43.36% up from the prior year.
  • Current Assets reached $894.0 million in Q4 2025 per CPRX's latest filing, up from $852.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $894.0 million in Q4 2025 to a low of $161.5 million in Q1 2021.
  • Average Current Assets over 5 years is $394.3 million, with a median of $259.4 million recorded in 2022.
  • Peak YoY movement for Current Assets: crashed 31.63% in 2023, then surged 184.33% in 2024.
  • A 5-year view of Current Assets shows it stood at $210.1 million in 2021, then soared by 52.69% to $320.8 million in 2022, then tumbled by 31.63% to $219.3 million in 2023, then soared by 184.33% to $623.6 million in 2024, then skyrocketed by 43.36% to $894.0 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Current Assets are $894.0 million (Q4 2025), $852.5 million (Q3 2025), and $758.7 million (Q2 2025).